A Randomized, Open, Two-Way Cross-Over, Single-Centre, Phase I Study to Assess the Counter regulatory Response during Hypoglycaemia in Healthy Male Volunteers after a Single Oral Dose of AZD1656 Suspension in Comparison with Insulin Infusion
Type 2 Diabetes
20 Years - 45 Years
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
No locations available
|Active Comparator: 1|
Single dose oral suspension given at one occasion.
|Active Comparator: 2|
Insulin infusion given during 3 hours at one occasion.